公开(公告)号：US10100130B2

公开(公告)日：2018-10-16

申请号：US15792373

申请日：2017-10-24

Applicant: UCB PHARMA S.A.

Inventor： David Paul Humphreys ,  Emma Dave ,  Laura Griffin ,  Sam Philip Heywood

IPC: C07H21/00 ,  C07K16/46 ,  C07K16/00 ,  C07K16/18 ,  C07K16/24

Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

公开(公告)号：US10087180B2

公开(公告)日：2018-10-02

申请号：US15318473

申请日：2015-06-11

Applicant: UCB Biopharma SPRL ,  Katholieke Universiteit Leuven, K.U.Leuven R&D

Inventor： Daniel James Ford ,  James Thomas Reuberson

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/496

Abstract: A series of pyrazolo[3,4-b]pyridine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

公开(公告)号：US10053464B2

公开(公告)日：2018-08-21

申请号：US15039073

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Daniel Christopher Brookings

IPC: C07D487/04 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377

Abstract: A series of substituted [1,2,4]triazolo[4,3-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US10000497B2

公开(公告)日：2018-06-19

申请号：US15318507

申请日：2015-06-11

Applicant: UCB Biopharma SPRL ,  Katholieke Universiteit Leuven, K.U.Leuven R&D

Inventor： Helen Tracey Horsley ,  Qiuya Huang ,  Judi Charlotte Neuss ,  James Thomas Reuberson ,  Bart Vanderhoydonck

IPC: C07D487/04 ,  C07D403/04 ,  A61K31/53 ,  A61K31/495 ,  A61P33/06 ,  A61P37/06

CPC classification number: C07D487/04 ,  A61K31/495 ,  A61K31/53 ,  C07D403/04 ,  Y02A50/411

Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

公开(公告)号：US09969728B2

公开(公告)日：2018-05-15

申请号：US15038239

申请日：2014-12-08

Applicant: UCB Biopharma SPRL

Inventor： Sabine Defays ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  James Andrew Johnson ,  Boris Kroeplien ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4184

CPC classification number: C07D471/04 ,  A61K31/4184 ,  A61K31/437 ,  A61K2300/00

Abstract: A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US09957255B2

公开(公告)日：2018-05-01

申请号：US15101073

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Daniel Christopher Brookings ,  Boris Kroeplien

IPC: C07D403/04 ,  C07D413/14 ,  C07D413/04 ,  C07D249/18 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D403/04 ,  A61K31/506 ,  A61K31/5377 ,  C07D249/18 ,  C07D413/04 ,  C07D413/14

Abstract: A series of substituted benzotriazole derivatives, being potent modulators of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US09926313B2

公开(公告)日：2018-03-27

申请号：US15101089

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/506

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506

Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US09908939B2

公开(公告)日：2018-03-06

申请号：US14914676

申请日：2014-08-26

Applicant: UCB BIOPHARMA SPRL

Inventor： Graham Craggs ,  Karine Jeannine Madeleine Hervé ,  Diane Marshall

IPC: C07K16/28 ,  C07K16/00 ,  C12P21/08 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.

公开(公告)号：US09873735B2

公开(公告)日：2018-01-23

申请号：US14697142

申请日：2015-04-27

Applicant: UCB Biopharma SPRL

Inventor： Ralph Adams ,  Pallavi Bhatta ,  Sam Philip Heywood ,  David Paul Humphreys

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US09867941B2

公开(公告)日：2018-01-16

申请号：US14437393

申请日：2013-10-21

Applicant: UCB Biopharma SPRL

Inventor： Martin John McLoughlin ,  Michael James David Heald ,  Cameron Townley Charles ,  Dylan Sanders Garrett ,  Kevin Richard Lozeau

IPC: A61M5/20 ,  A61M5/00 ,  A61M5/31 ,  A61M5/315 ,  A61M5/32 ,  H05K1/02 ,  H05K1/18 ,  A61M5/24

CPC classification number: A61M5/20 ,  A61M5/002 ,  A61M5/3134 ,  A61M5/31505 ,  A61M5/31515 ,  A61M5/3202 ,  A61M5/3204 ,  A61M5/326 ,  A61M2005/2013 ,  A61M2005/206 ,  A61M2005/208 ,  A61M2005/2477 ,  A61M2205/13 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/583 ,  A61M2205/586 ,  A61M2205/8206 ,  H05K1/0298 ,  H05K1/189 ,  H05K2201/052 ,  H05K2201/10151 ,  H05K2201/2009

Abstract: Provided is a drive unit for an auto-injector having a drive unit housing arranged for docking receipt of a syringe or of a cassette unit comprising a syringe movable from a rest position, in which a needle tip of the syringe is within the drive unit housing to a use position, in which the needle tip protrudes from a needle delivery aperture; and a drive arrangement including one or more electrically powered sources of axial drive; a first drive transfer element for advancing the syringe to said use position; and a second drive transfer element for moving a plunger into the barrel of the syringe to eject liquid contents thereof. The drive unit housing is provided with a skin sensor arrangement having an array of plural skin sensor electrodes located about the needle delivery aperture.